QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Powdered Formulation of CBD-Rich Hemp Oil Now Available to US Consumers

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, recently launched its ChrgD+ product, a water-soluble, multispectrum hemp oil in a powdered format powered by the company’s proprietary DehydraTECH(TM) technology for rapid CBD delivery (http://ibn.fm/Ljt7D). An article discussing the company reads, “The rapid biodelivery of CBD through DehydraTECH provides an avenue for safer, less-conspicuous consumption of CBD than inhaling it through smoke or vapor during a critical time when social acceptance of cannabis products is exploding age-old prohibitions but many legislative entities continue to struggle with regulatory issues on behalf of the public welfare. . . . ChrgD+ has been available in a limited number of retail stores throughout the Western United States, but the announcement that it is now available via commercial web delivery to locations where it can be legally consumed means that anyone has the potential to obtain it through the website www.ChrgD.life  without having to travel. Limited-time promotional offers and product updates are also available through the site.”

To view the full article, visit http://ibn.fm/Jm1uA

About Lexaria Bioscience Corp.

Lexaria is a global innovator in drug-delivery platforms. Its patented DehydraTECH drug-delivery technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bio-absorption, reduces time of onset, and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and more than 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php